NEW ASSAY DEVELOPMENT

开发和引入针对艾滋病毒的新疗法和局部杀微生物剂仍然是高度公共卫生优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界、私营部门或其他来源的有前途的治疗性和局部杀微生物剂候选药物的临床前开发。该合同提供产品开发服务，采用标准和高通量筛选(HTS)格式的生化和细胞分析。根据该合同提供的服务将帮助各种研究人员获得获得额外资金所需的关键数据，获得预期的合作伙伴关系(用于进一步开发或支持第一阶段试验)，并满足监管机构对研究新药(IND)申请的要求。将进行化验开发和验证，以确定和评估抗艾滋病毒治疗药物和局部杀微生物剂的疗效。主要的活动是开发和验证基于细胞的分析，作为潜在的介入性试剂，包括治疗和局部杀微生物剂。

The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides product development services utilizing biochemical and cell-based assays in both standard and high throughput screening (HTS) formats. The services provided under this contract will assist a wide variety of investigators in obtaining critical data needed to acquire additional funding, gain prospective partnerships (either for further development or to support Phase I trials), and fulfill regulatory agency requirements for investigational new drug (IND) applications. Assay development and validation will be conducted in order to identify and evaluate the efficacy of anti-HIV therapeutics and topical microbicides. The primary activity is for the development and validation of cell-based assays as potential interventional agents including therapeutics and topical microbicides.